Regulators licensed the 3 etanercept biosimilars discussed for all of the indications of the reference drug on the basis of the extrapolation of indications, a practice that the authors say rheumatologists may find “anomalous and a source of debate.”
A newly published review appearing in Biologics: Targets and Therapy discusses the existing literature on 3 biosimilar etanercept products: Benepali (developed by Samsung Bioepis and licensed in multiple non-US regions, sold in some areas under the name Brenzys), Erelzi (developed by Sandoz and approved in the United States and other regions), and Davictrel (developed by Hanwha Chemical Corporation and licensed in the Republic of Korea).
The review’s authors explain that the bioequivalence of each of the 3 products to the reference etanercept was demonstrated through pharmacodynamic and pharmacokinetic studies, as well as in head-to-head trials. Additionally, they write, regulators licensed the biosimilars for all of the indications of the reference drug on the basis of the extrapolation of indications, a practice that the authors say rheumatologists may find “anomalous and a source of debate.”
Read more about the extrapolation of indications.
The authors point out that consensus documents from the European League Against Rheumatism deem switching from the reference drug to the biosimilar to be safe and effective, that a switch may be undertaken in consultation with the patient. However, they write, evidence on efficacy and safety of nonmedical switching “is mostly based on a few observational, short-term studies on a small number of participants, thus seeming largely insufficient to recommend this procedure.”
They add that, in reported studies on nonmedical switching from the reference etanercept to the biosimilar resulted in discontinuation related to adverse events or loss of efficacy in 9% to 17% of patients. The authors state that this may be due to the fact that patients with treated in real-world practice may have significant differences from patients who were eligible for clinical trials.
The authors go on to say that biosimilars have “caught both physicians and patients by surprise,” and point to a German survey of 50 rheumatologists, which found that 95% of the clinicians who responded would prefer to use a reference product first, as an illustrative example. They also suggest that lack of patient education could be linked to the so-called “nocebo” effect, or negative outcomes linked with negative expectations about a drug. However, they write, because the nocebo effect is an undefined condition, it is challenging to address.
The authors conclude that biosimilar etanercept can be recommended as a first treatment, but that further evidence on switching to a biosimilar from the reference “would be preferable.”
Reference
Cantini F, Benucci M. Focus on biosimilar etanercept—bioequivalence and interchangeability. Biologics. 2018;12:87-95. doi: 10.2147/BTT.S126854.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: EC Approved Ustekinumab; Zymfentra Expansion; Biosimilar Policy Briefing
September 26th 2024The European Commission (EC) approved Celltrion's ustekinumab biosimilar for chronic inflammatory diseases, Celltrion expanded access to Zymfentra (subcutaneous infliximab-dyyb) through partnerships with Cigna and Express Scripts, and the Association for Accessible Medicines held a policy briefing addressing barriers to biosimilar adoption.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.